|More news on the ASAP front:|
ASAP Gets Drug Approval and Malaria Test Results
ALPINE, UT, Oct. 4 /PRNewswire-FirstCall/ - Clifton Mining Company (OTC:
CFTN) is pleased to announce that American Biotech Labs, a company in which
Clifton owns approximately 30% has just received its first international drug
approval and hospital trials have shown outstanding results using the ASAP
Solution(R) against a wide range of diseases including Malaria.
Hospital testing of the ASAP Solution(R), as an antibiotic alternative,
in Ghana, West Africa has met with such significant results that the Food and
Drug Board of Ghana has already approved the ASAP Solution(R) for drug
registration. Testing of the product in hospitals has been going on for over a
year, reports Keith Moeller VP, "We never dreamed that the human testing of
the product could have gone this well. We already have results in from the
first 60 patients, and we are waiting for information on approximately 120
In the testing, which was conducted in hospitals by medical doctors, the
ASAP Solution(R) was used as a treatment for a variety of diseases and
conditions such as malaria, fungal skin infections, vaginal infections,
urinary tract infections, tonsilitis, pharingitis, gonorrhea, conjunctivitis,
upper respiratory tract infections, nasal and sinus problems. Said Moeller,
"In the first 60 human cases which we have record of, the doctors reported no
failures at all. In fact, almost all conditions showed full recovery within
1-7 days, and in the case of one eye infection, the doctor reported immediate
Malaria is reportedly the number two infectious killer in the world,
killing approximately 1.5 million people, mostly children, annually. An
outbreak of several new cases was recently reported in the United States in
Virginia. Of the first 60 patents treated in the hospitals with the ASAP
Solution(R), there were eight reported malaria patients. Some of the cases
were reported as having "severe malaria". The patients ages were 8, 18, 35,
45, 51, 53, 56, and 75. The doctors reported that all eight malaria cases were
fully recovered within just seven days. Said Moeller, "We are very excited
about the test results and the drug approval. We can now sell the product in
West Africa and we expect to be shipping hundreds of thousands of bottles of
the ASAP Solution(R) to Africa before the end of the year. We are just on the
tip of the iceberg. Thousands of doctors and companies have been searching for
a treatment for malaria with limited success. Whereas, the test results of
ASAP Solution(R) are very positive. A new series of human trials has already
begun in Africa specializing in the treatment of malaria alone. We hope to
have those results soon. In conjunction with the results we released a few
weeks ago, showing the products ability to kill the MRSA super bacteria and
the new human test data including the treatment of malaria, we feel like the
mouse that roared!"
Clifton trades on the U.S. OTC: (CFTN).
Note: Any statements released by Clifton Mining Company that are forward
looking are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Editors and investors are cautioned
that forward looking statements invoke risk and uncertainties that may affect
the company's business prospects and performance. These include economic,
competitive, governmental, technological and other factors discussed in the
company's business plan and due-diligence information.
SOURCE Clifton Mining Company
Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Copyright © 1996-2002 PR Newswire Association LLC. All Rights Reserved.
A United Business Media company.